We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Celera and Ipsen Enter Research Collaboration to Develop Pharmacogenomic Tests

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Celera and Ipsen Enter Research Collaboration to Develop Pharmacogenomic Tests"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Celera and Ipsen announced that they have entered into a research collaboration to develop biomarker and pharmacogenomic tests for growth failure patients. The initial phase of the collaboration will focus on the discovery and characterization of genetic markers relating to this disease.

Assuming the first phase of this collaboration is completed successfully, a key aim thereafter will be to develop diagnostic predictors for use in Ipsen’s clinical trials, which would potentially form the basis for commercial companion diagnostic tests for Ipsen’s short stature therapies.

Celera will receive an undisclosed payment for the initial phase of this multi-year collaboration, and any future payment will depend on success of the initial phase.

“We’re pleased to enter this collaboration with Ipsen as it further reinforces Celera’s pharmacogenomic endeavors,” said Thomas White, Ph.D., Chief Scientific Officer at Celera.

“This is another example highlighting the importance of diagnostic and pharmaceutical companies working together to improve therapeutic availability through the practice of personalized disease management,” White added.

“Celera’s leadership in the field of genomics as applied to diagnostic and prognostic assays is expected to support Ipsen’s effort towards the optimal use of its hormone replacement medicines for the treatment of short stature,” said Jacques-Pierre Moreau, Executive Vice-President, Chief Scientific Officer of Ipsen.

“The potential outcomes from this collaboration could lead to the development of tests to support the rationale for use of our products in novel indications for short stature.”